Our new study reveals trends, R&D progress, and predicted revenues
Our new report discusses issues and events affecting the Parkinson’s disease therapeutics market. Our new report provides qualitative analyses to answer these key questions:
• How is the Parkinson’s disease therapeutics market evolving?
• What is driving and restraining the Parkinson’s disease therapeutics market?
• How will political and regulatory factors influence the regional markets and submarkets?
• Who are the leading Parkinson’s disease therapeutics companies, and what are their prospects over the forecast period?
• What are the predictions for M&A activity, consolidation for existing players and the potential prospects for new market entrants?
Forecasts from 2018-2028 and other analyses show you commercial prospects
Our new report provides quantitative analyses to answer these key questions:
• What are the market shares of the Parkinson’s therapeutics disease market in 2017?
• How will each of the drugs in the Parkinson’s therapeutics market grow over the forecast period and how much revenue will these drugs account for in 2028?
• What Parkinson’s disease drugs are in the development pipeline?
• How will each of Parkinson’s disease diagnostics market grow over the forecast period and how much revenue will these submarkets account for in 2028?
• How will the market shares of the national markets change by 2028 and which geographical region will lead the market in 2028?
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. We provide original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and STEP), company profiles and commercial developments.
Many opportunities exist for the treatment of Parkinson’s. Our new study shows you the most promising and lucrative parts of that CNS market, helping you stay ahead.
Discover sales predictions for the world market and submarkets
Discover in our report overall world revenue to 2028 for Parkinson’s disease medicines. Also explore individual revenue predictions to 2028 for six therapeutic submarkets at world level:
• Levodopa/ Carbidopa
• Dopamine Receptor Agonists
• MAO-inhibitors
• COMT-inhibitors
• Anticholinergics
• Other Therapeutic Options
Each submarket is further broken down by region: North America, South America, Europe, Asia-Pacific and ROW.
Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.
This report also breaks down the revenue forecast for the Global Parkinson’s Disease drugs market by Distribution Channel:
• Hospital Pharmacies
• Retailer Pharmacies
• Online Pharmacies
Each submarket is further broken down by region: North America, South America, Europe, Asia-Pacific and ROW.
This report also breaks down the revenue forecast for the Global Parkinson’s Disease drugs market by End-User:
• Hospitals
• Clinics
Each submarket is further broken down by region: North America, South America, Europe, Asia-Pacific and ROW.
What are the prospects in the leading regions and countries?
Developments worldwide expand the market for diagnosing, treating and monitoring neurodegenerative disorders. Developed and developing national markets hold high potential from 2017.
Our work also shows individual revenue forecasts to 2028 for 20 national markets:
• North America – US, Canada, Mexico
• South America – Brazil, Argentina, Paraguay, Bolivia
• Europe – Germany, France, UK, Italy, Spain and Russia
• Asia Pacific – China, Japan, India, Australia, Thailand
• ROW – Middle East, Africa
Leading companies and potential for market growth
In 2017 the overall Global Parkinson’s Disease drug market generated $4.10bn. Visiongain predicts its revenues in 2022 to reach $5.70bn. Our work shows you what organisation hold greatest potential. See profiles of leading companies in this sector:
• Astrazeneca
• Merck &Co.
• Novartis AG
• GlaxoSmith Kline
• Roche
• Pfizer
• Abbvie
• Biogen Inc.
• Acorda Therapeutics Inc
What affects producers of those medicines?
Our report discusses issues and events affecting that industry and market from 2017, including these:
• Research and development (R&D) – drugs, diagnostic tests, and related technologies
• Disease prevalence – expanding patient populations
• Disease-modifying drugs and obstacles to cures
• Regulatory guidelines – changes and opportunities.
• Drugs and related technologies to transform the market
• Biomarkers
• Deep brain stimulation (functional neuromodulation)
• Intellectual property (IP), licensing agreements and partnerships.
Please email sara.peerun@visiongain.com for a free report overview or call her on +44 207 549 9987
Our 152-page report provides 82 Tables and 85 Figures. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews trends and opportunities, and revenue predictions.
Benefit your work now through our updated study, gaining original industry and market analysis:
• Revenues for Parkinson’s disease treatments to 2028 – assess that overall world drugs market’s potential and get forecasted revenues for the six leading sub-classes: Levodopa/Carbidopa, Dopamine receptor agonists, COMT- and MAO-inhibitors, Anticholinergics, and other therapeutic options.
• National market forecasting to 2028 for 20 countries in the Americas, Europe, Asia, Middle East and Africa – explore the best regions for treatment demand, sales and growth
• R&D activities – see progress, trends and prospects in research and development, finding technological, clinical and commercial possibilities
• Analysis of what stimulates and restrains that industry and market – assess challenges and strengths there, helping you compete and gain advantages.
Please email sara.peerun@visiongain.com for a free report overview or call her on +44 207 549 9987
Companies listed in this report include:
Abbvie
Acorda Therapeutics Inc.
AstraZeneca
BioArtic
Biogen Inc.
Biotie Therapies
Center for Disease Control and Prevention (CDC)
Civitas Therapeutics
Food and Drugs Administration (FDA)
GlaxoSmithKline
Health Canada
IBM
Merck & Co.
Novartis
Parkinson’s Association
Parkinson’s Institute and Clinical Centre
Pfizer
Pharmaceuticals and Medical Devices Agency (PMDA)
Prothena
Roche
Servizio Sanitario Nazionale (SSN)
Takeda
UCB S.A
World Health Organisation (WHO)
Media Contact
Company Name: Visiongain Limited
Contact Person: Sara Peerun
Email: sara.peerun@visiongain.com
Phone: +44 207 3366100
Address:143 Airport House, Purley way
City: London CR0 0XZ
Country: United Kingdom
Website: https://www.visiongain.com/Report/2105/Global-Parkinson%E2%80%99s-Disease-Drug-Market-Forecast-2018-2028